Opko Health Initiates Phase III Trial of Bevasiranib for the Treatment of AMD

Opko Health Inc. announced the initiation of the Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD).
Medical News Today